Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,201–2,300 of 3,116
Zarówna, K., Pura, W., Mazur, J., Marciniak, J., Kosowski, M., Matecka, D., Śliwiński, W., & Chołuj, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4791
Glueck, C. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae435 · Cited by 1
Pharmakotherapie der chronischen Herzinsuffizienz
Oexner, R. R., & Frantz, S. (2026) · Kardiologie up2date · doi:10.1055/a-2701-0826
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
Zhang, J. K., Gao, G., He, M., & Sun, T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178921
Patel, H., Babli, S. A., Shah, S., Khambholja, S. H., Lingadahalli, T. D., Villarson, C., Rizwanullah, U., Kumarsivarajah, S., Masood, A., Rahming, N., et al. (2026) · Cureus · doi:10.7759/cureus.111786
“Real-world studies from North America, Europe, and East Asia have since provided evidence of consistent patterns across diverse healthcare settings [20-33].”
Said, J., Liegl, M., Pan, A. Y., & Dabrowski, E. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0227
“Depressive symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9), a validated screening tool commonly used in adolescents [16].”
Lu, D., Li, N., Yuan, Z., & Gao, Y. (2026) · Clinical Obesity · doi:10.1111/cob.70112
Hasebe, M., Su, C., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71035 · Cited by 1
Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane
Chen, P.-H., Abood, S., & Bloom, S. H. (2025) · Microvascular Research · doi:10.1016/j.mvr.2025.104880 · Cited by 1
Hypogonadism and Metabolic Disorders
Cignarelli, A., Genchi, V. A., & Jayasena, C. N. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_50-1 · Cited by 1
Bergia, R. E., Brown, A. W., Braun, M. M., & Messina, M. J. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100689 · Cited by 1
“…myriad health benefits independent of weight loss, opening the possibility of indications for EOMs extending across diverse domains such as cardiovascular [42], renal [43], hepatic [44], neurodegenerative [45], and even behavioral reward domains unrelated to food (e.g., compulsive shopping) [46].”
EFEITOS ADVERSOS FRENTE AO USO INDEVIDO DO OZEMPIC
Rigato, L. K., Missiato, M., Silva, O. A., Verdi, N. C., & Reis, D. G. D. (2025) · Revista Omnia Saúde · doi:10.69719/ros.v8.851
Moyal, J., & Rehany, B. (2026) · University of Toronto Medical Journal · doi:10.33137/utmj.v103i2.46711
Rassam, F., Lopez, E. A., Sass, S., Srikulmontri, T., Isaacs, E., Malin, J. H., Wattanachayakul, P., & Afolabi-Brown, O. (2026) · Journal of Arrhythmia · doi:10.1002/joa3.70455
“Semaglutide and liraglutide are GLP-1 RAs approved for obesity [5, 6].”
Heerspink, H. J. L., van Raalte, D. H., Tuttle, K., Cherney, D. Z. I., Bjornstad, P., Cao, D., Dimitriadis, G. K., Linetzky, B., Jouravskaya, I., Bunck, M. C. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70622 · Cited by 2
“Therapies targeting incretin hormones, such as tirzepatide, address this patho-physiological mechanism [4, 6, 11].”
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3375
SGLT-2-Inhibitoren oder GLP-1-RA - wer hat die Nase vorn?
Sonnet, M. (2024) · Info Diabetologie · doi:10.1007/s15034-024-4967-1
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
Herrington, W. G., & Haynes, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00025-2
Paccou, J. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000962
Wu, J., Lee, K.-W., Huang, S. H. M., Chang, H.-Y., & Lin, Y. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06269-8
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefits in patients with type 2 diabetes and obesity, including reduction in major adverse cardiovascular events and improvement in systemic inflammation and endothelial function [12, 13].”
Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity
Tseng, T., Chen, S. S., Chen, H.-Y., & Chang, R. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.006 · Cited by 2
Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
Shabanowitz, S., Clark, R., Allen, R. B., Chandran, M. M., & Yang, A. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70123
“However, the most common reason for discontinuation in our study was GI-related adverse effects, which is similar to large, randomized-controlled trials excluding KTRs [7, 8, 20].”
InfluentialTocci, G., Nardoianni, G., Pala, B., Zuppini, E., Gualtieri, P., Renzo, L. D., Valenti, V., Basolo, A., Salvetti, G., Santini, F., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104857
Moscucci, F., Tocci, G., Nardoianni, G., Savoia, C., Contino, V., Leo, G., Bocale, R., Desideri, G., & Baratta, F. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00819-z
Салухов, В. В., Arutyunov, G. P., Vasilyeva, I. A., Cherkashin, D. V., Prochik, Y. E., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-136
Oliveira-Gomes, D. D., de Majo, A. M., Ardila-Delgado, A. D., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01395-2
“Semaglu - tide significantly reduced MACE by 20% compared to pla - cebo (HR 0.80; 95% CI, 0.72–0.90), while also achieving a mean weight reduction of 9.4% versus 0.9% with placebo [39].”
InfluentialL’integrazione tra dieta e farmaci nell’era delle nuove terapie per l’obesità
Vitacolonna, E., Masi, D., & Watanabe, M. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01855-6
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Kwak, K. H., & Jung, C. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2803 · Cited by 1
“Extensive outcome studies show that GLP-1 receptor agonists reduce cardiovascular events in patients with obesity [14], and emerging evidence suggests that semaglutide and tirzepatide may provide additional benefits for heart failure (HF), particularly HF with preserved ejection fraction [15], and…”
Cuculić, M. T., Sergo, D., Kavazović, I., Peršić, V., Wensveen, F. M., & Wensveen, T. T. (2026) · Research Square · doi:10.21203/rs.3.rs-9020037/v1
Samuels, J. M., Williams, C. R., Patel, M. B., Self, W. H., Funk, L. M., Roumie, C. L., Spann, M. D., Northup, C. J., Ye, F., Irlmeier, R., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71320
Nguyen, N. H., Nguyen, T. V., Rudd, A., & Trung, T. Đ. (2024) · Springer eBooks · doi:10.1007/978-981-96-0221-6_7
Aggour, Y., & Salguero‐Gómez, R. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1800288
大塚, 英., 小林, 俊., & 岡島, 史. (2024) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.20.276
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
“Use of semaglutide 2.4 mg revealed a 20% reduction in MACE over a mean follow up of 40 months [37].”
InfluentialHu, F. B., Beleslin, B., Blaha, M. J., Kris-Etherton, P. M., Seligman, H. K., & Williams, K. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.025 · Cited by 1
Abdalla, S. A. M., Mohammed, H. O. A., Omer, E. O. E., Ahmed, I. O. I., Ahmed, W. A. O., Ginawi, K. O. T., Abdelfattah, R. E. M., Yousif, A. A. Z., & Ismail, K. I. A. (2026) · Cureus · doi:10.7759/cureus.111723
“…excluded because it enrolled patients with overweight or obesity and established cardiovascular disease but without diabetes, demonstrated a 20% reduction in MACE with subcutaneous semaglutide 2.4 mg (HR: 0.80, 95% CI: 0.72-0.90) [25], disentangling cardiovascular benefit from glucose lowering.”
InfluentialWhich heart failure phenotypes benefit from GLP-1 receptor agonists?
Deng, J. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00328-x
“In the SELECT trial, semaglutide reduced major adverse cardiovascular events in individuals with overweight or obesity without diabetes, indicating that mechanisms beyond glucose lowering are likely involved [2].”
Update kardiovaskuläre Prävention 2025
Wienbergen, H., Hanses, U., Kerniss, H., & Hambrecht, R. (2025) · Herz · doi:10.1007/s00059-025-05305-1
Obesity, lipids, inflammation, and healthy aging
Rikhi, R. R., & Shapiro, M. D. (2026) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2026.08.006
Agboola, F. O., Fahim, S. M., Lin, G. A., Lee, W., Richardson, M., & Rind, D. M. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.5.631 · Cited by 3
Meng, Y., Jin, T., Ren, L., Thompson, M. L., & Wang, Y. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0033 · Cited by 1
Epigenetic determinants of GLP-1 responsiveness: Integrating dietary modulation beyond genetics
Shin, H. R., Kim, T. Y., Min, K., Park, U., Oh, S. W., & Kim, J. K. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.09.004
Metabolic Syndrome: Redefine and Expand Its Reach, Yet Preserve Its Clinical Value
Saad, M. J. A., Santos, A., Geloneze, B., & Velloso, L. A. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.07.008 · Cited by 1
麦, 麦. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662319
Oral Incretin-Based Therapies for Weight Management
Cheng, H. E., Bonafede, M., & Shukla, A. P. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01456-6
“The additional indication of oral semaglutide for cardiovascular outcomes is based on the demonstrated 20% cardiovascular risk reduction with injectable semaglutide in the SELECT trial [15 ].”
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Tackling the epidemic of obesity and hypertension in children and young people
Haseler, E., & Sinha, M. D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001156 · Cited by 4
Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors
Elezaby, A., Nayor, M. G., & Alexander, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00096-0
李, 晓. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693223
Lytvyak, E., Grunvald, E. L., Shreekumar, D., Rye, P., Troshyn, O., Cawsey, S., Montaño‐Loza, A. J., Sharma, A. M., & Modi, R. (2025) · Obesities · doi:10.3390/obesities5030063
Ilany, J., Cohen, O., & Gorfine, M. (2025) · Research Square · doi:10.21203/rs.3.rs-6863965/v1
Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF
Ceravolo, R., Lucà, F., Gulizia, M. M., Nardi, F., Grimaldi, M., & Gelsomino, S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.06.015
Interdisziplinäre Adipositastherapie
Blank, S., & Otto, M. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2340-0932
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
“Mean weight loss approximately 9% sustained over 4 years, MACE reduction 20% (6, 100).”
Akimoto, T., & Nakajima, H. (2026) · Journal of Nihon University Medical Association · doi:10.4264/numa.85.1_11
Lee, W., Chen, H., Fang, C.-Y., Tsai, Y., Hsieh, Y.-Y., Chen, T., Fang, Y., Wu, P., Fang, H., & Liu, P. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611322555250219111038
Trenas, A., Prieto-Laín, N., Velasco, M. Á. P., Padilla-Leiva, C., Pérez-Ruiz, J. M., Ruíz-Rodríguez, F. I., Gómez‐Huelgas, R., Bernal-López, M. R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19060894 · Cited by 1
“…trial further demonstrated a reduction in major adverse cardiovascular events among overweight or obese individuals with established cardiovascular disease [13], while the FLOW trial reported significant renal and cardiovascular benefits in patients with type 2 DM and chronic kidney disease [14].”
Hafez, A. H., Mahmoud, A., Awad, K., Mohamed, M. R., Elbsiony, M., Nour, M., Aboalmaaty, Y. S., Elnaggar, K., Belasy, A., Mousa, H., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.07.025
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight lossPreprint
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · Research Square · doi:10.21203/rs.3.rs-9407045/v1
Inducing Factors of Obesity and Weight Management: Research Progress
Zhu, L. (2024) · Highlights in Science Engineering and Technology · doi:10.54097/4t09cm88
Cannon, E. J., Wang, W., Norby, F. L., Walker, R. F., Kulasingam, S., Chow, L. S., Farley, J. F., & Lutsey, P. L. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70711 · Cited by 1
Brown, H. M., Spies, N. C., Jia, W., Moley, J. R., Lawless, S., Roemmich, B., Brestoff, J. R., Zaydman, M. A., & Farnsworth, C. W. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae091 · Cited by 1
Redrawing the lines for the management of obesity in Asia
Khoo, B. C. E. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00155-5
Mazdutide and the metabolic treatment revolution
Li, X., Shao, B., Ruan, M., & Yang, S. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.003
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
“The SELECT trial provided dedicated cardiovascular outcome evidence for semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease but without diabetes, showing a significant reduction in major adverse cardiovascular events (Lincoff et al., 2023).”
InfluentialAcierno, C., Cavallo, M., D’Ardes, D., Boccatonda, A., Nilo, D., & Caturano, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188063 · Cited by 1
“Only part of that fall is attributable to weight loss: it was already evident at 4 to 8 weeks, before major weight loss had occurred, was present also among participants who did not lose weight, and was independent of low-density lipoprotein cholesterol and statin use [171,172].”
Translational pharmacology and biomarkers applied to GPCR
Özcelik, D., Andreetta, F., & van der Kam, E. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00036-4
Nabi, H. A., Dreher, L. A., Osta, S. A., & Shamoun, F. E. (2026) · Medical Sciences · doi:10.3390/medsci14020329
“GLP-1 RAs improve weight, glycemic control, inflammation, vascular endothelial function, and atherosclerotic outcomes, while major cardiovascular outcome trials have demonstrated reductions in adverse cardiovascular events in high-risk patients with and without diabetes [10–14].”
Kommentar zu „Semaglutid verbessert mit Herzinsuffizienz verbundene Symptome“
Laufs, U., & Schröder, S. C. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2347-8769
Celeski, M., Golino, M., Muro, F. M. D., Martino, G., Bernardi, M., Sasso, L. L., Gioia, G. D., Biccirè, F. G., Rubbio, A. P., Vecchione, C., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.058
Chen, S.-C., Huang, Y., Li, P.-Y., Chen, J.-C., Meyerowitz‐Katz, G., Yang, S., & Su, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71266
Bhaduri, G., BHATTACHARYYA, S., Mukherjee, S., & Gokalani, R. A. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02636-7
Brødsgaard, R. H., Dirksen, C., Pedersen, M. M., Kirk, J. W., Duun, O. M., Finken, M. T., Bojsen-Møller, K. N., & Bandholm, T. (2025) · medRxiv · doi:10.1101/2025.10.20.25337060
“Large-scale pharmaceutical trials have demonstrated the effectiveness of GLP-1RAs in reducing weight and disease-specific symptoms and risks in populations with obesity and comorbidities, such as type 2 diabetes (25), cardiovascular disease (26), and knee osteoarthritis (27).”
Li, L., Jin, L., & Wang, J. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s564902
“5–7 Among them, semaglutide—a next-generation weekly GLP-1RA formulation—has demonstrated remarkable reductions in major adverse cardiovascular events (MACE) in large-scale clinical trials: the LEADER trial reported a 13% relative risk reduction in MACE (including cardiovascular death, non-fatal…”
Treating Inflammation for Cardiovascular Prevention
Dons, M., Borchsenius, J., Abbate, A., Garshick, M. S., Biering‐Sørensen, T., & Weber, B. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01130-1 · Cited by 1
Economic evaluations of antiobesity medications: A systematic literature review
Jurković, M., Fajkić, A., Faour, A. K., Momčilović, M., Turčić, P., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70825
Wang, Y., Ma, J., Hu, Y., Desjardins, C., & Chen, Z. (2026) · Vessel Plus · doi:10.20517/2574-1209.2026.31
何, 雨. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151093
Inamine, S., & Uesato, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71190 · Cited by 1
Kardiometabolisches Syndrom – Pathophysiologie, Therapie und Prävention
Raeder, S. (2026) · Kardiologie up2date · doi:10.1055/a-2654-6802
GLP-1 receptor agonist use for obesity in service personnel
Jecks, N., Hughes, C., Macleod, N., & Gifford, R. M. (2025) · BMJ Military Health · doi:10.1136/military-2025-003159
Avivi, I., Zelmanoff, D. D., Golan, N., & Arbel, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02201-4
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Diastolic dysfunction and diabetes: the DIADAD study—a retrospective cohort study from Liverpool
Wali, L., Abbara, M. A., Ekhelikar, S., Pilling, J., Albouaini, K., & Murray, S. W. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag079
IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.107
From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease
Maggioni, A. P., Orso, F., Lucci, D., Luca, L. D., & Colivicchi, F. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134646
Highlighting the latest research: May 2026
McSharry, S., Binu, R., & Lotto, R. R. (2026) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2026.0029
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Core Trainee Prize Winner: Weight loss drugs: their role and potential future in orthopaedic surgery
Doyle, T. (2024) · Bone and Joint 360 · doi:10.1302/2048-0105.133.360143
Anti-obesity Pharmacotherapy for Patients with Genetic Obesity Disorders
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-04095-4_15
Kommentar zu „Herzinsuffizienz und Übergewicht: Semaglutid verbessert kardiovaskuläre Funktion“
Hellenkamp, K. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2183-4150
The Ischemia–Plaque Paradox: A Mechanistic Framework for Chronic Coronary Syndromes
Klein, L. W. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001461
The role of metabolic disorders in major depressive disorder
Sun, L., Qin, Y., Fan, X., Chen, J. K., & Du, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11969-7
We fixed the valve: it is time to treat the disease
Bayes-Genis, A., & Haring, B. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag085
Alshehri, W., Alzahrani, A. S., Alzahrani, N. A., Mahfouz, T., & Alsofyani, B. A. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20262169
Obesidad en España: un libro abierto que debemos leer
de Victoria, E. O. M., Vila, A. P., & Pineda, A. J. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.03.010
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
